Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 3
2016 2
2017 1
2018 1
2019 1
2020 6
2021 9
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.
Thornton CS, Caverly LJ, Kalikin LM, Carmody LA, McClellan S, LeBar W, Sanders DB, West NE, Goss CH, Flume PA, Heltshe SL, VanDevanter DR, LiPuma JJ. Thornton CS, et al. Ann Am Thorac Soc. 2024 Apr;21(4):595-603. doi: 10.1513/AnnalsATS.202306-576OC. Ann Am Thorac Soc. 2024. PMID: 37963297 Clinical Trial.
Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69-0.99; P = 0.034) and longer median time to next PEx (255 d vs. 172 d; P = 0.021) compared with virus negativity.Conclusions: More than one-third of STOP2 participant …
Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69-0.99; P = 0.034) and long …
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Rowe SM, Selvadurai H, Taylor-Cousar JL, Withers NJ, Ahluwalia N, Moskowitz SM, Prieto-Centurion V, Tan YV, Tian S, Weinstock T, Xuan F, Zhang Y, Ramsey B, Griese M; VX17-445-105 Study Group. Daines CL, et al. Eur Respir J. 2023 Dec 7;62(6):2202029. doi: 10.1183/13993003.02029-2022. Print 2023 Dec. Eur Respir J. 2023. PMID: 37945033 Free PMC article. Clinical Trial.
BACKGROUND: In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis (CF) 12 years of age who have at least one F508del allele. The aim of this study is to assess long- …
BACKGROUND: In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious a …
Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study.
Martiniano SL, Caceres SM, Poch K, Rysavy NM, Lovell VK, Armantrout E, Jones M, Anthony M, Keck A, Nichols DP, Vandalfsen JM, Sagel SD, Wagner B, Xie J, Weaver K, Heltshe SL, Daley CL, Davidson RM, Nick JA; Investigators of the Cystic Fibrosis NTM Consortium. Martiniano SL, et al. J Cyst Fibros. 2024 Jan;23(1):50-57. doi: 10.1016/j.jcf.2023.08.007. Epub 2023 Sep 4. J Cyst Fibros. 2024. PMID: 37666709 Free article.
Active participants who have not met these criteria are re-consented every 5 years to enable long-term participation. RESULTS: The primary endpoint will summarize the proportion of participants who meet the NTM-PD diagnosis definition. ...
Active participants who have not met these criteria are re-consented every 5 years to enable long-term participation. RESULTS: The pr …
Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations.
Szczesniak R, Andrinopoulou ER, Su W, Afonso PM, Burgel PR, Cromwell E, Gecili E, Ghulam E, Goss CH, Mayer-Hamblett N, Keogh RH, Liou TG, Marshall B, Morgan WJ, Ostrenga JS, Pasta DJ, Stanojevic S, Wainwright C, Zhou GC, Fernandez G, Fink AK, Schechter MS. Szczesniak R, et al. Ann Am Thorac Soc. 2023 Jul;20(7):958-968. doi: 10.1513/AnnalsATS.202209-829OC. Ann Am Thorac Soc. 2023. PMID: 36884219
Marginal models consistently estimated less rapid lung function decline than mixed-effects models across scenarios, except for short-term follow-up (both were 1.4). Rate of decline estimates from nonlinear models diverged by age 30. ...Conclusions: Differences were as high …
Marginal models consistently estimated less rapid lung function decline than mixed-effects models across scenarios, except for short-term …
Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Davis CS, Faino AV, Onchiri F, Gibson RL, Merjaneh L, Ramsey BW, Rosenfeld M, Cogen JD. Davis CS, et al. Ann Am Thorac Soc. 2023 Jan;20(1):75-82. doi: 10.1513/AnnalsATS.202203-201OC. Ann Am Thorac Soc. 2023. PMID: 36044723
CF Foundation PEx guidelines note that a short course of systemic corticosteroids may offer benefit without contributing to long-term adverse effects. However, insufficient evidence exists to recommend systemic corticosteroids for PEx treatment. ...
CF Foundation PEx guidelines note that a short course of systemic corticosteroids may offer benefit without contributing to long-term …
The lung allocation score and other available models lack predictive accuracy for post-lung transplant survival.
Brahmbhatt JM, Hee Wai T, Goss CH, Lease ED, Merlo CA, Kapnadak SG, Ramos KJ. Brahmbhatt JM, et al. J Heart Lung Transplant. 2022 Aug;41(8):1063-1074. doi: 10.1016/j.healun.2022.05.008. Epub 2022 May 20. J Heart Lung Transplant. 2022. PMID: 35690561 Free PMC article.
BACKGROUND: Improved predictive models are needed in lung transplantation in the setting of a proposed allocation system that incorporates longer-term post-transplant survival in the United States. Allocation systems require accurate mortality predictions to justly allocat …
BACKGROUND: Improved predictive models are needed in lung transplantation in the setting of a proposed allocation system that incorporates l …
Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.
Ramos KJ, Guimbellot JS, Valapour M, Bartlett LE, Wai TH, Goss CH, Pilewski JM, Faro A, Diamond JM; CFLTC Study Group. Ramos KJ, et al. J Cyst Fibros. 2022 Sep;21(5):745-752. doi: 10.1016/j.jcf.2022.04.009. Epub 2022 Apr 23. J Cyst Fibros. 2022. PMID: 35474016 Free PMC article.
Further study is needed to determine the risks and benefits of ETI in the CF lung transplant population given the potential for drug interactions, side effects leading to discontinuation of ETI, and the possible mechanisms for ETI to positively impact long-term post-transp …
Further study is needed to determine the risks and benefits of ETI in the CF lung transplant population given the potential for drug interac …
A population-level strain genotyping method to study pathogen strain dynamics in human infections.
Morgan SJ, Durfey SL, Ravishankar S, Jorth P, Ni W, Skerrett DT, Aitken ML, McKone EF, Salipante SJ, Radey MC, Singh PK. Morgan SJ, et al. JCI Insight. 2021 Dec 22;6(24):e152472. doi: 10.1172/jci.insight.152472. JCI Insight. 2021. PMID: 34935640 Free PMC article.
A hallmark of chronic bacterial infections is the long-term persistence of 1 or more pathogen species at the compromised site. ...
A hallmark of chronic bacterial infections is the long-term persistence of 1 or more pathogen species at the compromised site. ...
Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community.
Kapnadak SG, Morrell ED, Wai TH, Goss CH, Shah PD, Merlo CA, Hachem RR, Ramos KJ. Kapnadak SG, et al. J Heart Lung Transplant. 2022 Jan;41(1):20-23. doi: 10.1016/j.healun.2021.10.008. Epub 2021 Oct 22. J Heart Lung Transplant. 2022. PMID: 34785136 Free PMC article.
Chronic lung allograft dysfunction (CLAD) is the most important long-term complication after lung transplant (LTx), and clinical experience suggests significant variability in its management. ...
Chronic lung allograft dysfunction (CLAD) is the most important long-term complication after lung transplant (LTx), and clinical expe …
COVID-19 outcomes in people with cystic fibrosis.
Burgel PR, Goss C. Burgel PR, et al. Curr Opin Pulm Med. 2021 Nov 1;27(6):538-543. doi: 10.1097/MCP.0000000000000823. Curr Opin Pulm Med. 2021. PMID: 34620788 Free PMC article. Review.
Vaccination appears important to all PwCF, with special priority on developing adequate vaccination scheme for transplant recipients. Long-term effects of COVID-19 on the CF population remains unknown. SUMMARY: The COVID-19 pandemic has caused significant impacts on PwCF a …
Vaccination appears important to all PwCF, with special priority on developing adequate vaccination scheme for transplant recipients. Long- …
27 results